Roginolisib (hemifumarate)

Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases[1].

Product Specifications

CAS Number

[1621688-31-0]

Product Name Alternative

MSC2360844 (hemifumarate) ; IOA-244 (hemifumarate)

UNSPSC

12352005

Target

PI3K

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/roginolisib-hemifumarate.html

Concentration

10mM

Purity

99.80

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=NN(C2=CC=C(CN3CCOCC3)C=C2)C(C4=CC=CC(F)=C45)=C1CS5(=O)=O)N6CCOCC6.OC(/C=C/C(O)=O)=O

Molecular Formula

C26H27FN4O5S.1/2C4H4O4

Molecular Weight

584.62

References & Citations

[1]Haselmayer P, et al. Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Front Immunol. 2014 May 22;5:233.